Nektar Therapeutics (NKTR) had quite a Wednesday morning, with shares jumping after the biotech company dropped some compelling long-term data on its experimental eczema therapy. The news? Sustained and even deepening disease control through one year, which is exactly what you want to see when you're trying to crack into the multibillion-dollar atopic dermatitis market.

The data comes from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study, which tested rezpegaldesleukin for moderate-to-severe atopic dermatitis. William Blair liked what they saw enough to upgrade Nektar after reviewing the results, which showed that both monthly and quarterly dosing regimens kept the disease under control across multiple measures.

Here's where it gets interesting: patients on the 24 µg/kg monthly and quarterly regimens maintained the highest response rates at week 52 across several key metrics, including Eczema Area Severity Index EASI-75, EASI-90, validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS) response. Less frequent dosing with sustained control is a meaningful advantage for patients dealing with chronic conditions.

But the real standout? A meaningful proportion of patients actually achieved new responses at week 52, including EASI-75, EASI-90, Itch NRS, and vIGA-AD 0/1. That suggests the therapy isn't just maintaining control—it's getting better with time, even with less frequent dosing.

Complete Clearance Numbers Impress Analysts

The maintenance data showed a two to five-fold increase in the percentage of patients who achieved EASI-100—complete disease clearance—in the 24 µg/kg monthly and quarterly dosing regimens. Among all patients who were re-randomized from week 16 to week 52, monthly maintenance dosing pushed EASI-100 response from 4% to 22%, while quarterly dosing increased it from 9% to 18%.

For patients who already showed an EASI-75 or vIGA-AD response at maintenance baseline, the numbers were even better. Monthly dosing increased EASI-100 response from 6% to 30%, and quarterly dosing boosted it from 14% to 27%.

William Blair upgraded the stock to Outperform, with analyst Andy Hsieh noting the therapy continues to demonstrate deepening of response and durability with longer-term data. "We are particularly impressed by the EASI-100 (complete disease clearance) attainment in roughly 20% of the patients re-randomized following induction, and about 30% for those who already had a response (EASI-75 or vIGA-AD 0 or 1)," Hsieh wrote in an investor note Tuesday.

How Does It Stack Up Against Competition?

Hsieh also pointed out that EASI-75 and EASI-90 results showed remarkable similarity, and while quarterly dosing showed numerically lower vIGA-AD scores, the range of 59% to 65% still beats competitor datasets hovering around 50%.

For EASI-75 specifically, the range of 74% to 92% for the quarterly maintenance dose of rezpegaldesleukin came in numerically higher than Sanofi SA (SNY) and Regeneron Pharmaceuticals Inc.'s Dupixent, which hit 72%. That's a notable edge in a crowded and competitive market.

Raising Capital to Push Forward

On Tuesday, Nektar Therapeutics announced a public offering to raise $300 million via equity, likely to fund further development and commercialization efforts as the therapy moves closer to potential approval.

NKTR Price Action: Nektar Therapeutics stock closed Tuesday at $56.00, rocketing 51.07% in regular trading. The rally continued into Wednesday's premarket session, with shares climbing another 5.54% to $59.10.